<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910789</url>
  </required_header>
  <id_info>
    <org_study_id>S2AEG</org_study_id>
    <nct_id>NCT04910789</nct_id>
  </id_info>
  <brief_title>Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Controlled Study Comparing Surgical Efficacy Between Transhiatal/Transabdominal and Thoracoabdominal Approach for Patients With Siewert II Adenocarcinoma of Esophagogastric Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare transhiatal / transabdominal approach with thoracoabdominal approach for Siewert&#xD;
      II adenocarcinoma of esophagogastric junction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To compare the safety and clinical efficacy between transhiatal/transabdominal and&#xD;
      thoracoabdominal approach for Siewert Ⅱ adenocarcinoma of esophagogastric junction.&#xD;
&#xD;
      Methods: A prospective, multi-center, randomized, controlled study will be performed.&#xD;
      Patients who meet the eligibility criteria will be registered in the study and undergo&#xD;
      radical surgery via transhiatal/transabdominal or thoracoabdominal approach. The data of&#xD;
      preoperative, intraoperative, postoperative and follow-up will be recorded and analyzed.&#xD;
&#xD;
      The primary endpoints :3-year disease-free survival. The secondary endpoints:(1) Surgery and&#xD;
      oncology indicators ;(2) The incidences of postoperative complications and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Proportion of patients without tumor recurrence from surgery to the end of the 3-year follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of R0-resection</measure>
    <time_frame>About 10 days after surgery</time_frame>
    <description>The proportion of patients undergoing radical resection in all surgical patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of lymph node dissections and the positive</measure>
    <time_frame>About 10 days after surgery</time_frame>
    <description>The number of lymph node dissections and the positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of postoperative hospitalization</measure>
    <time_frame>Within 6 months after surgery</time_frame>
    <description>Time from end of surgery to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidences of early postoperative complications</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>The incidence of postoperative complications such as pneumonia, pleural effusion, anastomotic stenosis, anastomotic leakage, duodenal stump fistula, pancreatic fistula, abdominal abscess, and deep vein thrombosis (%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of perioperative mortality</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>The incidence of death due to the surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Adenocarcinoma of Esophagogastric Junction</condition>
  <arm_group>
    <arm_group_label>Thoracoabdominal approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radical surgery should be finished via Thoracoabdominal approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transhiatal/transabdominal approach</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical surgery should be finished via transhiatal/transabdominal approach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transhiatal/transabdominal approach</intervention_name>
    <description>Radical surgery should be finished via transhiatal/transabdominal approach</description>
    <arm_group_label>Transhiatal/transabdominal approach</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thoracoabdominal approach</intervention_name>
    <description>Radical surgery should be finished via thoracoabdominal approach</description>
    <arm_group_label>Thoracoabdominal approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1.18~75 years old&#xD;
&#xD;
          -  2.The tumor center located at the esophagogastric junction(EGJ) line from 1cm above to&#xD;
             2cm below(SiewertⅡ) .&#xD;
&#xD;
          -  3.Histological diagnosis of adenocarcinoma&#xD;
&#xD;
          -  4. American Society of Anesthesiologists(ASA) physical status class is less than or&#xD;
             equal to 3&#xD;
&#xD;
          -  5.Informed consent of patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Patients with distant metastasis (M1) or invasion of surrounding organs&#xD;
&#xD;
          -  2.History of esophagectomy and gastrectomy (including endoscopic mucosal&#xD;
             resection/endoscopic submucosal dissection for gastric cancer and esophageal cancer)&#xD;
&#xD;
          -  3.History of other malignant tumors within 5 years&#xD;
&#xD;
          -  4.The researcher believes that the patient is not suitable to participate in the&#xD;
             clinical trial&#xD;
&#xD;
          -  5.Patients who persist in withdrawing from clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinxin Wang, Dr</last_name>
    <phone>+8613811858199</phone>
    <email>301wxx@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinxin Wang, Dr.</last_name>
      <phone>+8613811858199</phone>
      <email>301wxx@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lin Chen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

